ArticleJournal of cachexia, sarcopenia and muscle2021
The role of recipient myosteatosis in graft and patient survival after deceased donor liver transplantation.
Article in Journal of cachexia, sarcopenia and muscle, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Impact of myosteatosis on outcomes after liver transplantation: a systematic review and meta-analysis.Hepatology international · 2025Pooled it
- Sarcopenia As a Predictor of Survival and Complications of Patients With Cirrhosis After Liver Transplantation: A Systematic Review and Meta-Analysis.Clinical transplantation · 2025Pooled it
- Increased skeletal muscle loss as a predictor of recurrence in postoperative lung cancer patients.Irish journal of medical science · 2026Article
- Myosteatosis as a prognostic biomarker for post-transplant survival and cardiometabolic outcomes: A retrospective study.Canadian liver journal · 2026Article
- Developing an explainable machine learning model using body composition to predict cardiovascular mortality in initial dialysis patients: a multicenter study.Frontiers in physiology · 2026Article
- Preoperative CT-derived skeletal muscle phenotypes, postoperative complication burden, and long-term survival after liver transplantation: a 90-day landmark mediation analysis.Frontiers in nutrition · 2026Article
- Quality and Quantity? The Clinical Significance of Myosteatosis in Various Liver Diseases: A Narrative Review.Journal of clinical and translational hepatology · 2025Review
- Myosteatosis: Epidemiological Insights, Functional Decline, and Diagnostic Advances.Current obesity reports · 2025Review
- The Impact of Sarcopenia, Myosteatosis, and Visceral Adiposity on Renal Transplantation Outcomes.Medicina (Kaunas, Lithuania) · 2025Article
- Automated abdominal CT imaging biomarkers and clinical frailty measures associated with postoperative deceased-donor liver transplant outcomes.European radiology · 2025Article
- Type II fibre atrophy and nuclear disruption in decompensated cirrhosis.JHEP reports : innovation in hepatology · 2025Article
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Impacts Long-Term Outcomes After Curative-Intent Surgery for Hepatocellular Carcinoma.Alimentary pharmacology & therapeutics · 2025Article
- Skeletal MuscleJournal of cachexia, sarcopenia and muscle · 2025Article
- Myosteatosis as an independent predictor for all-cause and cardiac mortality in initial-dialysis patients: a multicenter, retrospective cohort study.Frontiers in physiology · 2025Article
- Geriatric nutritional risk index and body composition dictate the prognosis of elderly patients with intrahepatic cholangiocarcinoma.Frontiers in nutrition · 2025Article
- Diagnosis of Sarcopenia and Myosteatosis by Computed Tomography in Patients with Esophagogastric and Pancreatic Cancer.Cancers · 2024Article
- Association of myosteatosis with short-term outcomes in patients with acute-on-chronic liver failure.Scientific reports · 2024Article
- NAFLD Is Associated With Quiescent Rather Than Active Crohn's Disease.Inflammatory bowel diseases · 2024Article
- Prognostic Value of Myosteatosis and Creatinine-to-Cystatin C Ratio in Patients with Pancreatic Cancer Who Underwent Radical Surgery.Annals of surgical oncology · 2024Article
- Current approach to the diagnosis of sarcopenia in cardiovascular diseases.Frontiers in nutrition · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMyosteatosis is associated with perioperative outcomes in orthotopic liver transplantation (OLT). Here, we investigated the effects of body composition and myosteatosis on long-term graft and patient survival following OLT.
methodsClinical data from 225 consecutive OLT recipients from a prospective database were retrospectively analysed (May 2010 to December 2017). Computed tomography-based lumbar skeletal muscle index (SMI) (muscle mass) and mean skeletal muscle radiation attenuation (SM-RA) (myosteatosis) were calculated using a segmentation tool (3D Slicer). Patients with low skeletal muscle mass (low SMI) and myosteatosis (low SM-RA) were identified using predefined and validated cut-off values.
resultsThe mean donor and recipient age was 55 ± 16 and 54 ± 12 years, respectively. Some 67% of the recipients were male. The probability of graft and patient survival was significantly lower in patients with myosteatosis compared with patients with higher SM-RA values (P = 0.011 and P = 0.001, respectively). Low skeletal muscle mass alone was not associated with graft and patient survival (P = 0.273 and P = 0.278, respectively). Dividing the cohort into quartiles, based on the values of SMI and SM-RA, resulted in significant differences in patient but not in graft survival (P = 0.011). Even though multivariable analysis identified low SM-RA as an important prognostic marker (hazard ratio: 2.260, 95% confidence interval: 1.177-4.340, P = 0.014), myosteatosis lost its significance when early mortality (90 days) was excluded from the final multivariable model. Patients with myosteatosis showed significantly higher all-cause mortality and in particular higher rates of deaths due to respiratory and septic complication (P = 0.002, P = 0.022, and P = 0.049, respectively).
conclusionsPreoperative myosteatosis may be an important prognostic marker in patients undergoing deceased donor liver transplantation. The prognostic value of myosteatosis seems to be particularly important in the early post-operative phase. Validation in prospective clinical trials is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.